Cochrane · systematic review · CD008238

Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Gurion, R, Belnik‐Plitman, Y, Gafter‐Gvili, A, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Haematology2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 1 · 7.1%Very low 1 · 7.1%Low 8 · 57.1%Moderate 3 · 21.4%High 1 · 7.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

All cause mortality for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

5 questions

Outcome	Effect	Evidence	Status / GRADE
All cause mortality ‐ 30 days	RR 0.97 [0.8, 1.18]	11 studies · 3319 participants	Low Downgraded: risk of bias
All cause mortality ‐ End of	RR 1.01 [0.98, 1.05]	14 studies · 4029 participants	Low Downgraded: risk of bias
All cause mortality subgroup analysis age>60	RR 1.01 [0.97, 1.06]	7 studies · 2035 participants	Low Downgraded: risk of bias
All‐cause mortality subgroup analysis age< 60	RR 1.08 [0.97, 1.2]	5 studies · 1079 participants	Low Downgraded: risk of bias
All‐cause mortality ‐ sensitivity analysis	RR 1.03 [0.99, 1.07]	10 studies · 3405 participants	High

Overall survival for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Overall survival	HR 1 [0.93, 1.08]	11 studies · 3335 participants	Low Downgraded: risk of bias

Complete remission for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
complete response	RR 1.03 [0.99, 1.07]	17 studies · 4774 participants	Moderate Downgraded: risk of bias

Disease free survival for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Disease free survival	OR 1 [0.9, 1.13]	7 studies · 1639 participants	Low Downgraded: risk of bias

Relapse rate for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Relapse rate	RR 0.97 [0.89, 1.05]	10 studies · 2189 participants	Low Downgraded: risk of bias

Bacteremias for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia

2 questions

Outcome	Effect	Evidence	Status / GRADE
Bacteremia	RR 0.96 [0.82, 1.12]	7 studies · 1638 participants	Moderate Downgraded: imprecision
Very wide CI	no estimate extracted	1 participants	Ungraded

Invasive fungal infections for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Invasive fungal infection	RR 1.4 [0.9, 2.19]	4 studies · 929 participants	Low Downgraded: risk of bias, imprecision

Episodes of febrile neutropenia for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Episodes of febrile neutropenia	RR 0.98 [0.94, 1.03]	9 studies · 2140 participants	Moderate Downgraded: risk of bias

Adverse events requiring discontinuation of CSFs for prevention and treatment of infectious complications in patients with acute myelogenous leukemia

Population: Prevention and treatment of infectious complications in patients with acute myelogenous leukemia

1 question

Outcome	Effect	Evidence	Status / GRADE
Adverse events requiring discontinuation of CSFs	RR 1.33 [1, 1.76]	4 studies · 770 participants	Very low Downgraded: risk of bias, imprecision